ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,766.70
-0.28%
S&P ASX All Technology
3,056.50
-0.63%
Brent Oil
82.825
-0.02%
US Dollar vs AUD
1.50143
-0.07%
Bitcoin
67,803.00
-2.29%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Ocugen Inc (OCGN)

  7. Ocugen Inc (OCGN) News

OCGN

Ocugen (OCGN)

Ocugen Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:OCGN
DateTimeSourceHeadlineSymbolCompany
20/05/202421:00GlobeNewswire Inc.Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024NASDAQ:OCGNOcugen Inc
18/05/202406:30Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:OCGNOcugen Inc
15/05/202420:30GlobeNewswire Inc.Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene TherapyNASDAQ:OCGNOcugen Inc
15/05/202405:54Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCGNOcugen Inc
14/05/202422:00GlobeNewswire Inc.Ocugen Provides Business Update with First Quarter 2024 Financial ResultsNASDAQ:OCGNOcugen Inc
14/05/202421:18IH Market NewsUS Futures Remain Steady Amid Wall Street Caution Ahead of April PPI ReportNASDAQ:OCGNOcugen Inc
14/05/202420:32Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OCGNOcugen Inc
11/05/202406:15Edgar (US Regulatory)Form 8-A12G - Registration of securities [Section 12(g)]NASDAQ:OCGNOcugen Inc
11/05/202406:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCGNOcugen Inc
11/05/202406:05GlobeNewswire Inc.Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common StockNASDAQ:OCGNOcugen Inc
10/05/202421:45GlobeNewswire Inc.Ocugen to Present at May 2024 Investor ConferencesNASDAQ:OCGNOcugen Inc
03/05/202421:30GlobeNewswire Inc.Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial ResultsNASDAQ:OCGNOcugen Inc
02/05/202421:15GlobeNewswire Inc.Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World CongressNASDAQ:OCGNOcugen Inc
29/04/202420:45GlobeNewswire Inc.Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024NASDAQ:OCGNOcugen Inc
26/04/202423:05GlobeNewswire Inc.UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual MeetingNASDAQ:OCGNOcugen Inc
26/04/202420:30GlobeNewswire Inc.Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual MeetingNASDAQ:OCGNOcugen Inc
19/04/202421:13GlobeNewswire Inc.Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene TherapyNASDAQ:OCGNOcugen Inc
12/04/202421:30GlobeNewswire Inc.Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital MarketsNASDAQ:OCGNOcugen Inc
10/04/202421:02GlobeNewswire Inc.Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa IndicationNASDAQ:OCGNOcugen Inc
08/04/202420:30GlobeNewswire Inc.Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa IndicationNASDAQ:OCGNOcugen Inc
05/04/202422:02GlobeNewswire Inc.Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic AtrophyNASDAQ:OCGNOcugen Inc
02/04/202423:00GlobeNewswire Inc.Ocugen Provides Business Update with Certain Financials for the Year Ending 2023NASDAQ:OCGNOcugen Inc
02/04/202409:08GlobeNewswire Inc.Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt DiseaseNASDAQ:OCGNOcugen Inc
02/04/202408:43GlobeNewswire Inc.Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023NASDAQ:OCGNOcugen Inc
18/03/202421:30GlobeNewswire Inc.Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical OfficerNASDAQ:OCGNOcugen Inc
13/03/202423:00GlobeNewswire Inc.Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410NASDAQ:OCGNOcugen Inc
06/03/202423:30GlobeNewswire Inc.Ocugen to Present at Investing in Cures SummitNASDAQ:OCGNOcugen Inc
29/02/202400:00GlobeNewswire Inc.Ocugen Clinical Showcase Webcast Now AvailableNASDAQ:OCGNOcugen Inc
27/02/202400:30GlobeNewswire Inc.Ocugen Chairman and CEO to present at Abu Dhabi Family Office SummitNASDAQ:OCGNOcugen Inc
23/02/202408:05GlobeNewswire Inc.Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410STNASDAQ:OCGNOcugen Inc
 Showing the most relevant articles for your search:NASDAQ:OCGN

Your Recent History

LSE
AWGS
LSE
13RX
Toy.mf.n.23
COIN
BRMMUSD
GDAX
MSOLUSD
Marinade staked SOL
BIT
UV8BQU
UniCredit Bank
USOTC
SYCHF
Sanyo Chemical Industries (PK)
LSE
73LG
Kib Sukuk 30
USOTC
DMTTF
Small Pharma (QB)
NASDAQ
ONSIW
COIN
VCONETH
Voicecoin
BIT
F16930
Vontobel Financial Produ...
COIN
NETCUSD
ASX
CBALOM
LSE
ZT15
Toy.canada 28
AQSE
CORP.GB
iShares Global Corp Bond...
COIN
AIIIIGBP
AI Token
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved